Parkinson disease: diagnosis and differential

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Parkinson disease is a progressive synucleinopathy in which nigrostriatal dopamine loss produces a characteristic motor syndrome, but diagnosis remains clinical. Bradykinesia is not simply moving slowly: repetitive actions lose amplitude or rhythm, initiation becomes effortful and automatic movements such as arm swing, blinking and facial expression diminish. Rigidity is velocity-independent resistance, sometimes enhanced by movement of the opposite limb. A classic rest tremor is asymmetric and reduces during purposeful movement, yet a substantial minority of patients never develop it.

History should reconstruct the sequence rather than count current symptoms. Slow unilateral handwriting, reduced arm swing and dexterity followed by tremor fits idiopathic disease. Falls in the first year, rapid wheelchair dependence, early severe dysphagia, inspiratory stridor, disproportionate urinary retention, cerebellar signs, pyramidal signs, vertical gaze palsy, cortical sensory loss or absence of meaningful levodopa response are diagnostic warning signs. Cognitive impairment may occur in Parkinson disease, but very early dementia with visual hallucinations can indicate dementia with Lewy bodies.

No blood test, MRI feature or response trial substitutes for specialist assessment. Medication review, neurological examination and selective imaging identify reversible or atypical causes. NICE recommends clinical diagnosis using established criteria, rapid untreated referral, and periodic diagnostic review. Communicate uncertainty honestly: an early label may evolve as longitudinal signs and treatment response become apparent, and this is good diagnostic practice rather than failure.

Key points

Parkinsonism requires bradykinesia plus rigidity, rest tremor or postural instability not better explained by another disorder; slowness alone is insufficient.
True bradykinesia is progressive reduction in speed or amplitude during repetitive movement, seen in finger tapping, hand opening, pronation-supination, toe tapping or gait.
Idiopathic Parkinson disease usually begins asymmetrically and combines limb signs with reduced arm swing, hypomimia, quiet voice and a good sustained levodopa response.
Non-motor features can precede movement symptoms: anosmia, REM sleep behaviour disorder, constipation, depression and autonomic symptoms increase suspicion but are not independently diagnostic.
NICE advises rapid referral, before starting treatment, to a specialist with expertise in differential diagnosis when Parkinson disease is suspected.
Early recurrent falls or vertical gaze palsy suggest PSP; severe early autonomic failure or stridor suggests MSA; marked apraxia, cortical sensory loss or alien-limb phenomena suggest corticobasal syndrome.
Dopamine-blocking antipsychotics and antiemetics commonly cause or worsen parkinsonism. The syndrome is often symmetrical, but asymmetry does not completely exclude a drug contribution.
Vascular parkinsonism more often affects gait and lower limbs with cerebrovascular disease, while normal-pressure hydrocephalus adds cognitive and urinary features and ventriculomegaly.
Structural MRI is used for atypical features or alternative pathology, not to prove routine Parkinson disease; dopamine-transporter SPECT helps when essential tremor and degenerative parkinsonism remain clinically indistinguishable.
Review the diagnosis regularly, generally every six to twelve months, and reopen it when treatment response, progression or new signs no longer fit Parkinson disease.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Sporadic alpha-synucleinopathy

Most Parkinson disease is sporadic, with age-related cellular vulnerability and polygenic influences promoting nigrostriatal degeneration and alpha-synuclein accumulation.

Inherited Parkinson disease

Rare pathogenic variants affect lysosomal, mitochondrial and synaptic biology, particularly in young-onset or strongly familial disease.

Environmental modifiers

Population-level exposures can alter risk, but no single toxin or lifestyle factor establishes the diagnosis in an individual.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Alpha-synuclein accumulation
Misfolded alpha-synuclein disrupts synapses, protein clearance and cellular energy systems within vulnerable neurons as disease progresses.
2
Nigrostriatal dopamine loss
Degeneration of substantia-nigra neurons reduces dopamine delivery to striatum and distorts basal-ganglia movement selection over time.
3
Motor circuit dysfunction
Reduced facilitation of desired movement and excessive inhibitory output produce bradykinesia, rigidity, rest tremor and gait change.
4
Wider network spread
Autonomic, sleep, olfactory, mood and cognitive systems become involved, often before or beyond the core motor syndrome.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Bradykinetic-rigid syndrome

Repetitive finger taps become progressively smaller and slower, passive movement reveals rigidity, facial expression and blink rate fall and gait has reduced arm swing with short steps and turning en bloc.

Tremor-dominant presentation

A unilateral pill-rolling rest tremor emerges when walking or distracted and reduces with action, while subtle bradykinesia or rigidity confirms parkinsonism rather than isolated tremor.

Prodromal non-motor clues

Longstanding hyposmia, dream enactment, constipation, depression and autonomic symptoms may predate motor disease, but common prevalence means they only modify probability in context.

Atypical parkinsonism

Early falls, severe autonomic failure, gaze palsy, cerebellar or pyramidal signs, rapid progression, disproportionate axial rigidity, apraxia or cortical sensory loss demand an alternative diagnosis.

Medicine-induced syndrome

Symptoms begin after an antipsychotic, metoclopramide, prochlorperazine, valproate or another dopamine-interfering medicine, often with bilateral signs and coexisting akathisia or tardive movements.

Acute or stepwise courseRed flag

Sudden onset, clear focal deficits or stepwise lower-body gait decline is not typical idiopathic Parkinson disease and should trigger stroke, vascular, toxic, metabolic or structural investigation.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Expert clinical history and examinationFirst step
Why
Confirm bradykinesia, define accompanying signs and compare the longitudinal pattern with recognised Parkinson and atypical criteria.
Interpretation and limitations
Examine repetitive upper- and lower-limb movement, rigidity, rest and action tremor, gait, pull response, eye movements, cerebellar, pyramidal, cortical and autonomic features. Observe before and during walking.
02
Detailed medicine and exposure review
Why
Identify dopamine-receptor blockers, toxin exposure and medicines causing tremor or slowness that can be modified safely.
Interpretation and limitations
Record start dates and dose changes, including antipsychotic and antiemetic use. Do not stop essential psychiatric treatment abruptly; coordinate substitutions and allow months for recovery before assuming degeneration.
03
MRI brain for atypical features
Why
Exclude stroke, tumour, hydrocephalus, extensive vascular disease and other structural explanations when the phenotype is not straightforward.
Interpretation and limitations
Routine MRI may be normal in Parkinson disease and suggestive signs of PSP or MSA are supportive rather than individually diagnostic. Interpret through neuroradiology and clinical progression.
04
Iodine-123 FP-CIT SPECT
Why
Support distinction between degenerative presynaptic parkinsonism and essential tremor when expert clinical examination remains uncertain.
Interpretation and limitations
An abnormal scan supports nigrostriatal deficit but does not reliably distinguish Parkinson disease from MSA, PSP or other degenerative parkinsonism; medication interference and technical quality matter.
05
Targeted blood and physiological tests
Why
Investigate metabolic, systemic or autonomic alternatives selected by age, tempo and examination.
Interpretation and limitations
Consider thyroid function, B12, liver or renal profile, copper studies in a young patient, lying and standing blood pressure, post-void residual or genetic assessment only when the phenotype warrants them.
06
Levodopa response over follow-up
Why
Provide longitudinal supportive evidence after a specialist has made the treatment decision.
Interpretation and limitations
A clear sustained functional response supports Parkinson disease; a poor response is meaningful only after adequate dose, duration, absorption and adherence are considered, and does not by itself name the alternative.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Drug-induced parkinsonism

Dopamine-blocker exposure and often bilateral symptoms support an iatrogenic syndrome, although asymmetry and unmasked degeneration can occur.

Essential tremor

Bilateral action tremor without bradykinesia or rigidity favours essential tremor; rest tremor alone does not establish Parkinson disease.

Atypical neurodegeneration

Early falls, gaze palsy, severe autonomic failure, stridor, cerebellar or cortical signs favour PSP, MSA or corticobasal syndrome.

Vascular disease or NPH

Lower-body gait disorder with cerebrovascular lesions or ventriculomegaly and urinary-cognitive features suggests vascular parkinsonism or hydrocephalus.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01First suspicionRefer before treatingFirst stepTremor, stiffness, slowness, gait or balance features raise possible Parkinson disease.

1Confirm objective bradykinesia, examine tremor and rigidity, observe gait and eye movements, measure standing blood pressure and screen cognition, mood, swallowing, sleep and falls.
2Reconcile prescribed and non-prescribed medicines, plotting dopamine-blocker exposure and symptom onset, and investigate any abrupt, focal or systemic presentation urgently.
3Refer rapidly and untreated to a neurologist or geriatrician with diagnostic expertise, providing the chronology, examination, medicines, falls and functional impact rather than beginning a trial in primary care.

02Atypical signsChallenge the labelEarly course includes falls, autonomic failure, gaze, cortical, cerebellar, pyramidal or rapidly progressive features.

1Define which red flag occurred and when relative to first motor symptom; check postural blood pressure, bladder emptying, eye movements, speech, swallowing and limb praxis directly.
2Arrange MRI and targeted autonomic, cognitive, metabolic or other tests to exclude structural and reversible causes, recognising that supportive imaging cannot establish neuropathology.
3Seek a movement-disorder review and communicate provisional diagnoses, safety issues and symptom treatment without overpromising certainty or levodopa responsiveness.

03Longitudinal confirmationUse evolution as evidenceA specialist diagnosis has been made and response and progression can be observed.

1Document baseline motor laterality, gait, activities, non-motor burden and treatment timing so later change is measurable rather than based on a general impression.
2Review the diagnosis at least every six to twelve months, checking sustained response and the emergence of autonomic, ocular, cognitive, bulbar, cortical or cerebellar signs.
3Reclassify and refer for additional expertise when the trajectory is atypical, while preserving physiotherapy, occupational, speech, driving and falls support independent of the label.

Key medicines and prescribing safety4 treatments · regimens, roles and cautions

Preserves an untreated examination and follows NICE advice for rapid expert differential diagnosis.

No pre-referral dopaminergic trial

Do not initiate a diagnostic test dose before specialist assessment when Parkinson disease is newly suspected.

This does not mean withholding established time-critical Parkinson medicines from a diagnosed patient; deterioration or swallowing failure needs urgent medicines reconciliation.

Removes a potentially reversible cause or amplifier of parkinsonism while maintaining treatment of the original condition.

Dopamine-blocking medicine review

Reduce or substitute only through the relevant psychiatric, medical or pharmacy plan; never use abrupt generic withdrawal.

Antipsychotic relapse, nausea control and withdrawal risks matter. If antipsychotic therapy remains essential, specialist selection of a lower motor-risk option is required.

A clinically meaningful response supports idiopathic disease and treats motor impairment once diagnosis and goals are agreed.

Levodopa after specialist diagnosis

The specialist chooses a co-beneldopa or co-careldopa formulation and titrates it to functional response.

Nausea, postural hypotension, hallucinations, sleepiness and later fluctuations can occur; response must be judged after adequate exposure and medicines must not be stopped suddenly.

Addresses gait, falls, activities, communication, saliva and swallowing even while the diagnostic label remains provisional.

Supportive non-pharmacological referral

Prescribe goal-led physiotherapy, occupational therapy and speech-and-language input rather than a fixed medicine dose.

Generic exercise advice is insufficient when freezing, postural instability, aspiration or unsafe work and driving tasks require individual assessment.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Falls and mobility loss

Freezing, postural instability and orthostatic hypotension cause fractures, fear, deconditioning and dependence as disease advances over time.

Cognitive and psychiatric symptoms

Dementia, hallucinations, depression and impulse-control problems can cause more disability and safeguarding risk than limb signs.

Dysphagia and aspiration

Progressive bulbar and cough dysfunction leads to weight loss, medication difficulty and aspiration pneumonia in advanced disease.

Autonomic and sleep morbidity

Constipation, urinary dysfunction, syncope, REM sleep behaviour disorder and daytime sleepiness impair safety and quality of life.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Record laterality and repeated-movement decrement, rigidity, tremor context, gait, turning and postural stability at baseline and subsequent specialist reviews.
Ask specifically about falls, faintness, urinary retention, erectile dysfunction, stridor, dream enactment, hallucinations, cognition, speech and swallowing because patients may not connect them to movement disease.
Review the relationship between symptoms and dopamine-blocking medicines, and ensure any psychiatric substitution is monitored jointly rather than attributed automatically to degeneration.
Reassess the diagnosis every six to twelve months or sooner with rapid progression, early falls, poor treatment response or new ocular, cortical, cerebellar or pyramidal signs.
Discuss DVLA notification, occupational hazards, falls prevention and home safety once a chronic movement disorder could affect vehicle or machinery control.
Safety-net acute focal deficit, fever with severe rigidity, sudden confusion, repeated syncope, aspiration symptoms and abrupt loss of mobility for emergency assessment.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Bradykinesia has decrement

Arthritis, depression and frailty can cause global slowness; progressive amplitude or speed reduction during repetitive movement is more neurologically specific.

Tremor is optional

Absence of rest tremor does not exclude Parkinson disease, while isolated tremor without bradykinesia does not establish parkinsonism.

DaTscan has limits

Presynaptic dopaminergic deficit separates essential tremor from degenerative parkinsonism but cannot reliably name which degenerative syndrome is present.

Symmetry is a clue

Marked early asymmetry supports idiopathic disease, whereas symmetrical onset raises medication or vascular causes, though neither pattern is absolute.

Red flags are temporal

Urinary symptoms or falls late in established Parkinson disease mean something different from severe retention or repeated falls in the first year.

Diagnosis can mature

Regular reconsideration allows an early Parkinson label to evolve into MSA, PSP, CBS or another explanation as discriminating features emerge.

11Common pitfallsFrequent interpretation and management errors.

01
Diagnosing Parkinson disease from tremor alone without demonstrating bradykinesia or rigidity.
02
Starting levodopa in primary care before the recommended untreated specialist assessment.
03
Using a dopamine-transporter scan to claim distinction between Parkinson disease and MSA or PSP.
04
Missing prochlorperazine, metoclopramide or antipsychotic exposure in a patient with new symmetrical parkinsonism.
05
Reassuring after a normal routine MRI even though Parkinson diagnosis is clinical and red flags persist.
06
Keeping the original label unchanged despite early falls, gaze palsy, severe autonomic failure or absent adequate levodopa response.